Johnson & Johnson sued the U.S. Health and Human Services Department on Tuesday, accusing the agency of blocking its plan to ...

The Food and Drug Administration (FDA) has approved a new presentation of Selarsdi ™ (ustekinumab-aekn), a biosimilar to Stelara ® (ustekinumab), expanding the product’s indications to include ...

The active ingredient in Stelara is ustekinumab. (An active ingredient is what makes a drug work.) The drug comes as a liquid solution you receive as a subcutaneous injection (an injection under ...

Johnson & Johnson seeks to charge 340B-enrolled disproportionate share hospitals full price for Xarelto and Stelara and issue ...

Before injecting Stelara for the first time, talk with your doctor. They’ll show you how to inject the drug safely and help determine which injection site is best for you. Subcutaneous ...

The rebate game played by drug makers and pharmacy benefit managers limits optimal biosimilar competition. As a result, U.S.

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Companies in the multi-billion dollar psoriasis market are vying to be the next standard of treatment, and a flood of new data from three drugs showing them superior to Humira and Stelara.

Johnson & Johnson’s inflammatory disease drug Stelara has been approved in Europe for ulcerative colitis (UC), a new use for the multibillion dollar blockbuster. The European Commission cleared ...

This includes large pharmacy chains and pharmacy benefit managers, leading to abuses that undermine patient benefits. Also ...

Johnson & Johnson has sued a U.S. government agency over a closely watched dispute focusing on payment methods for some ...

Goldman Sachs downgraded Option Care Health (OPCH) to Neutral from Buy with a $27 price target. The firm had previously held the view that ...